Clinical Research Details Clinical Research Feasibility and efficacy of CYP2D6 genotype-guided management of opioid analgesics in patients undergoing elective ventral hernia repairs: A pilot pragmatic trial Study Description Due to variations in the CYP2D6 gene, individuals metabolize opioid medications differently. For patients undergoing ventral hernia repair (VHR), this can increase the risk of post-operative pain and toxicity. Motivated by this, we propose a pragmatic pilot trial evaluating CYP2D6 genotyping to provide more personalized post-operative pain control among patients undergoing VHR at our academic medical center. Inclusion/Exclusion Criteria Inclusion: All adults > 18 years age undergoing a Ventral Hernia Repair ≥1.5 cm in diameter with mesh Exclusion: Ventral Hernia Repairs <1.5 cm, those who plan to undergo a primary repair without a mesh, in an emergency setting, patients receiving chronic opioid therapy (defined as use of opioids on most days for >3 months), or patients with an allergy to opioids. Women of childbearing potential who have a positive pregnancy result as part of their standard pre-surgical workup will be excluded. Investigators Jana M. Sacco, M.D. Surgery